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Introduction
Heart transplantation has emerged as the definitive cure for end-stage heart failure. Short-term outcomes after heart transplant have improved substantially, but longterm outcomes remain poor because of malignancy, graft failure, and cardiac allograft vasculopathy (CAV), a condition that appears to be preceded by endothelial dysfunction. 1, 2 In the heart transplant recipient, subclinical coronary endothelial injury occurs early via a variety of mechanisms, such as donor injury and immune activation, and may be the precipitating event in CAV. These injuries promote a state of inflammation characterized by upregulation of inflammatory cytokines and growth hormones. 3 As a result, abnormalities in vasomotor tone, as demonstrated by abnormal coronary responses to acetylcholine and abnormal brachial artery dilatation, have been 4, 5 The ability to identify abnormal vascular function noninvasively and before the development of CAV could be useful in identifying heart transplant recipients at greater risk for CAV.
Evaluation of arterial elasticity has the potential to provide important insight into the early functional changes that precede intimal thickening and the subsequent development of CAV. In the general population, small (SAE) and large (LAE) artery elasticity measured via the radial artery have been demonstrated to be prognostic. LAE, a marker of vascular stiffness that implies structural damage to the conduit arteries, is associated with cardiovascular risk. 6,7 SAE, derived from diastolic radial pulse contour analysis, more closely correlates with endothelial (dys)function, as measured from reflected waves from the resistive vessels, and implies a functional change in vascular function. 8, 9 Noninvasively measured arterial elasticity may be useful in evaluating risk in heart transplant recipients. The goal of this preliminary study is to characterize SAE and LAE in heart transplant recipients by comparison with asymptomatic individuals free of overt cardiovascular disease and by identification of demographic and clinical factors associated with arterial elasticity in this unique population.
Methods

study design
The study protocol and informed consent procedures were approved by the University of Minnesota Human Subjects Review Committee. Investigations were in accordance with the Declaration of Helsinki. We conducted cross-sectional analyses to both test for differences in SAE and LAE between heart transplant recipients and normal controls and evaluate the associations between arterial elasticity and relevant demographic and clinical variables among heart transplant recipients. Data for heart transplant recipients were collected as part of a larger, ongoing, cross-sectional study to evaluate markers of endothelial function and their associations with the presence and severity of CAV. Control participants were selected from our existing prevention center database.
Participants
Heart transplant recipients undergoing routine annual clinical evaluations at the University of Minnesota Medical Center were invited to participate in the study. Patients were eligible if they were aged 18 years or older and had received their transplant at least 12 months ago. Patients were excluded if they had more than a single heart transplant; received multiple organs; had an active infection; were experiencing acute rejection (grade 3a or greater); or had stage 4 chronic kidney disease, defined as a glomerular filtration rate lower than 30 mL/minute per 1.73 m 2 , or acute renal failure. Sixtythree heart transplant recipients were enrolled.
Control subjects (n = 1,808) for these analyses were retrospectively selected from a database of asymptomatic patients who had undergone a cardiovascular screening (which included measurement of SAE and LAE) at the University of Minnesota Rasmussen Center for Cardiovascular Disease Prevention.
Data collection
Data for control group participants (age, sex, SAE, and LAE) were abstracted from the existing patient database at the Rasmussen Center. Heart transplant recipients underwent a clinical evaluation at study entry and completed a medical and demographic questionnaire to obtain information on history of tobacco use, diabetes, hypertension, and current medical therapy. This history was supplemented and confirmed by data collected from our center's clinical transplant database.
Participants in the heart transplant group were also assessed for CAV with coronary angiograms, read by two interventional cardiologists. The presence of CAV was defined as a stenosis of 25% or greater in an epicardial vessel on angiogram. The severity of CAV was assessed and scored on the basis of the following system: grade 0, 0% stenosis; grade 1, 25% stenosis or less; grade 2, 26%-50% stenosis; grade 3, 51%-75% stenosis; and grade 4, more than 75% stenosis. Moderate CAV was defined as grade 3 CAV or greater.
Measurement of arterial elasticity
For determination of artery elasticity, radial artery pulse waveforms were acquired from all participants (control subjects and heart transplant subjects), using the CVProfilor (Hypertension Diagnostics, Inc, Eagan, MN, USA), which performs radial artery pulse wave analysis. The radial artery wave form was obtained using a sensor positioned over the artery and calibrated using an oscillometric method with a cuff on the opposite arm and a calibration system internal to the device. The device uses a previously described algorithm that is applied to define a third-order equation that replicates the diastolic decay and waveform. 9 C1 or capacitive compliance (LAE) and C2 or oscillatory compliance (SAE) are calculated from the radial artery pulse waveforms, using a modified Windkessel formula. This methodology, which has previously heart transplantation and arterial elasticity been described, provides a convenient way to assess both large conduit artery and small, resistance circulatory function. 10, 11 Tracings were reviewed for accuracy of measurement and sensitivity of capturing the waveform. Three measurements were obtained from each subject. The mean SAE and LAE values for each subject were used in the analysis.
Statistical analysis
Continuous measurements were summarized using the mean, standard deviation, median, and range. Counts and percentages were calculated for categorical variables. A P-value of ,0.05 was considered to be statistically significant. Linear regression was used to compare SAE and LAE between heart transplant recipients and normal controls, both univariately and adjusting for age and sex. Linear regression limited to heart transplant recipients was also used to identify associations between SAE or LAE and the following variables: age, sex, presence of CAV, total cholesterol, high-density lipoprotein and low-density lipoprotein cholesterol, triglycerides, triglyceride/high-density lipoprotein ratio, systolic and diastolic blood pressure, transplant duration, history of ischemic cardiomyopathy (as reason for transplant), history of rejection, history of CMV infection, and immunosuppressant therapy (calcineurin inhibitor, mycophenolate mofetil, sirolimus). Two models were fit for each outcome. The first model used a binary covariate for the presence of CAV (grade 2 or above), and the second model used a binary covariate for the presence of moderate CAV (grade 3 or above).
Results
Participant characteristics
Baseline characteristics are reported in Table 1 . Most (81%) participants were men. The mean age was 58 ± 12 years, and the mean duration of transplant was 5.8 ± 5.6 years. Forty-eight percent of patients were transplanted for ischemic cardiomyopathy. Fifty-one percent of heart transplant recipients had CAV, and 23% had moderate CAV. The mean low-density lipoprotein level was 85 mg/dL; 86% of patients were receiving statin therapy. In our sample of heart transplant recipients, 83% were taking a calcineurin inhibitor, either tacrolimus or cyclosporine. Seventy-three percent were taking mycophenolate mofetil, 29% sirolimus, and 3% prednisone, and less than 2% were taking azathioprine.
association of heart transplantation with sae and lae
In heart transplant recipients, the mean LAE was 14.9 ± 5.1 mL/mmHg ×10, and the mean SAE was 4.5 ± 2.1 mL/mmHg ×100. In the control group, the mean LAE was 16.6 ± 5.58 mL/mmHg ×10, and the mean SAE was 6.5 ± 3.17 mL/mmHg ×100. In unadjusted analyses ( Table 2) , both LAE and SAE were significantly lower in heart transplant recipients than in control subjects (P , 0.02 and P , 0.0001, respectively). After adjustment for age and sex ( Table 2) , heart transplant continued to be significantly associated with reduced LAE and SAE (P , 0.01 and P , 0.0001, respectively). CAV was found in 51% of the heart transplant recipients. Exclusion of these patients from the analysis did not alter the basic finding, and after adjustment for age and sex, LAE and SAE were still significantly reduced in heart transplant recipients (n = 26) compared with the LAE and SAE values for control subjects (P = 0.04 and P = 0.0006, respectively).
association of caV risk factors with sae and lae
Results for the univariate analyses are shown in Table 3 . Reduced LAE was significantly associated with female sex (P = 0.0006) and increased triglyceride levels (P = 0.04). Specifically, female sex was associated with a significant reduction in LAE of 5.4 mL/mmHg ×10, and increasing triglyceride level was associated with reduction in LAE. Older age, history of ischemic cardiomyopathy as indication for heart transplant, and higher triglyceride levels were significantly associated with reduced SAE. Increase in age by 1 year resulted in a 0.06 mL/mmHg ×100 reduction in SAE (P = 0.007), history of ischemic cardiomyopathy reduced Results for the stepwise multiple regression models are shown in Table 4 . In the final models that adjust for selected risk factors for CAV, female sex retained its significant, independent association with reduced LAE (β = −7.26; P , 0.0001). In addition, history of ischemic cardiomyopathy was found to be associated with a 3.24 mL/mmHg ×10 reduction in LAE (P = 0.01). Older age and history of ischemic cardiomyopathy remained significantly associated with reduced SAE. In addition, female sex was associated with a 2.16 mL/mmHg ×100 reduction in SAE (P , 0.002), and the presence of moderate CAV was associated with a 1.51 mL/mmHg ×100 reduction in SAE (P , 0.02). Two other clinical variables, low-density lipoprotein levels and duration of heart transplant, were associated with increased SAE (0.02 and 0.14 mL/mmHg ×100 increases in SAE, respectively). History of CMV infection, rejection, or current use of MMF, CNI, or sirolimus were associated with arterial elasticity.
Discussion
The results from our analyses indicate that heart transplantation is independently associated with reduced SAE and LAE when compared with healthy controls. There are multiple known contributors to abnormal vascular function after transplant, including T-cell and B-cell activation, donor injury, effects of immunosuppression, and the presence of more common risk factors such as hypertension and diabetes. The anatomical effects of the heart transplant surgery itself and resulting abnormal ventriculo-vascular coupling may also propagate vascular dysfunction. Our results suggest that these multiple transplant-related mechanisms, leading to alterations in vascular tone, ultimately may result in reduced SAE and LAE.
To generate hypotheses about the possible mechanisms of arterial stiffness in heart transplant recipients, and to preliminarily explore the potential of arterial elasticity measurements as functional biomarkers for CAV, we examined the associations among SAE/LAE, CAV, and several known risk factors of CAV. Patient age, sex, history of ischemic heart disease, duration of transplant, low-density lipoprotein levels, and presence of CAV were all significant correlates of artery elasticity in our sample.
Measurement of SAE by pulse contour analysis reflects the functional behavior of the small and resistance arteries, which is affected by alterations in the concentrations of endothelial-derived substances and structural changes. In our heart transplant sample, increasing age, female sex, history of ischemic cardiomyopathy, and presence of moderate CAV were independently associated with reduced SAE. In nontransplant populations, SAE is an independent risk marker for cardiovascular events, including myocardial infarction, coronary bypass surgery, coronary angioplasty, peripheral arterial disease, and cerebrovascular events, but the relationship between SAE and CAV has not been described. 10, [12] [13] [14] [15] Coronary endothelial dysfunction precedes the development of CAV, and minimal lesions have been shown to cause coronary endothelial dysfunction. 16 In our study, moderate CAV was significantly associated with reduced SAE. We unexpectedly found that increasing duration of transplant was associated with increased (improved) SAE (Figure 1 ). This could potentially be explained by time-related positive vascular remodeling, as the size of the vessel influences SAE, although we would have expected a similar association between transplant duration and LAE, which was not observed. An alternative explanation is the "healthy worker" effect; that is, heart transplant recipients who have survived longer may, in general, be healthier than nonsurvivors, who would not have been included in our analysis. Another hypothesis would be an improvement in ventriculo-arterial coupling late after heart transplant. To a lesser degree, large artery stiffness is a predictor of cardiovascular events and is determined by age, sex, and blood pressure in the nontransplant population. 9, [17] [18] [19] [20] [21] In our sample of heart transplant recipients, female sex and ischemic heart disease were significantly and independently associated with reduced LAE, but not CAV. This lack of association may be related to the unique pathophysiologic and anatomic characteristics of CAV, which differentiate it from atherosclerotic disease.
Peripheral endothelial function has been shown to improve after heart transplantation, but the degree of improvement may be influenced by the etiology of heart failure. 22, 23 In previous work, endothelial dysfunction measured by aortic augmentation index was associated with etiology of heart failure and improved after transplantation. 24 Contrary to these findings, persistent peripheral endothelial dysfunction, evaluated by skin laser-Doppler perfusion, has been documented in patients up to 13 years after transplant. 25 In a small study of 20 heart transplant recipients, brachial artery reactivity appeared to be normal in heart transplant recipients with antecedent nonischemic cardiomyopathy at an average of 33 ± 8 months after transplant but remained reduced in recipients with history of ischemic cardiomyopathy. 22, 26 We found a similar association between prior ischemic cardiomyopathy and SAE, suggesting that antecedent coronary artery disease, with the attendant inflammatory milieu and vascular injury, plays a significant role in determining endothelial function after transplant, despite improvements in hemodynamics and neurohormonal regulation.
The development of management strategies for CAV is limited by a lack of sensitive, practical, and prognostic screening and diagnostic tests. The ability to assess changes in vascular environment before the development of CAV would greatly enhance our ability to prevent CAV while limiting the heart transplant recipient's exposure to repeated coronary angiograms. Because our analyses were crosssectional, we cannot draw conclusions about the predictive value of SAE and LAE. Nonetheless, our finding of an association between reduced SAE and the presence of moderate CAV is promising for future studies evaluating the role of 
Limitations
The use of angiogram instead of intravascular ultrasound could have led to an underestimation of the degree of CAV and, subsequently, misclassification. Coronary angiogram, however, represents the gold standard for the diagnosis of CAV, and despite the increased sensitivity of intravascular ultrasound, coronary angiogram mirrors clinical practice.
The small sample size limited the ability to investigate more thoroughly the transplant-specific factors that might uniquely contribute to arterial elasticity. We acknowledge that a heart failure population may have provided a more suitable baseline control group; however, we believe the current comparison is valid in characterizing arterial elasticity in a quiescent, asymptomatic heart transplant population and provides useful information on this modality in the heart transplant recipient. In addition, the associations demonstrated were adjusted for etiology of heart failure, a potential determinant of endothelial function before transplant. Because the association of SAE with CAV was present after adjusting for etiology, we believe this analysis does account for factors that influence endothelial function that may have been present before transplant during heart failure. Finally, we acknowledge that causation cannot be concluded from a cross-sectional design, and longitudinal research is needed to determine the direction of the associations reported here. Nonetheless, this study does provide an important and novel snapshot of the peripheral vascular environment in heart transplant recipients and identifies several potential determinants of arterial stiffness after transplantation. Studies are in progress to evaluate the role of SAE as a predictor of CAV and related events.
Conclusion
In conclusion, our findings support the hypothesis that heart transplantation is independently associated with decreased endothelial function and increased arterial stiffness, as indicated by reduced SAE and LAE, respectively. There are some similarities in correlates of vascular stiffness between heart transplant recipients and nontransplanted patients (eg, age, female sex, and history of native CAD); however, the presence of moderate angiographic CAV was significantly and independently associated with reduced SAE. This finding suggests it may be possible to screen and identify patients at risk for CAV using a clinically applicable, noninvasive method. This needs to be confirmed through longitudinal study.
